Centre for Urology Research, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD, 4229, Australia.
Visceral Pain Research Group, Human Physiology, Centre for Neuroscience, College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Arch Toxicol. 2020 Aug;94(8):2785-2797. doi: 10.1007/s00204-020-02773-8. Epub 2020 May 22.
The cytotoxic drugs cyclophosphamide (CPO) and ifosfamide (IFO) cause toxic urological effects due to the production of urinary metabolites that cause bladder inflammation. This study aimed to identify changes in the bladder afferent system following treatment with these drugs that might explain reported urological adverse effects. Intravesical pressure and afferent nerve activity were recorded during bladder distension and drug administration in isolated bladders from mice, 24 h after intraperitoneal treatment with cyclophosphamide (100 mg/kg), ifosphamide (200 mg/kg) or saline (control). In isolated bladders, total afferent nerve activity at maximum bladder distension was increased from 182 ± 13 imp/s in control animals, to 230 ± 14 imp/s in CPO-treated (p < 0.05) and 226 ± 17 imp/s in IFO-treated (p < 0.001) mice. Single fibre analysis revealed the increase resulted from an enhanced activity in low threshold, wide dynamic range fibres (23.3 ± 1.9 imp/s/fibre in controls to 31.5 ± 2.5 (p < 0.01) in CPO and 29.9 ± 2.0 imp/s/fibre (p < 0.05) in IFO treated). CPO treatment was accompanied by an increase in urinary frequency in vivo, but was not associated with increases in urothelial release of ATP or acetylcholine, bladder compliance or spontaneous muscle activity. Also, CPO-treatment did not affect afferent nerve responses or pressure responses to purinergic, muscarinic or nicotinic agonists. This is the first report of CPO and IFO-induced changes in specific populations of bladder afferents, namely an increase in low threshold, wide dynamic range fibres. These effects appear to be direct and not secondary to increases in smooth muscle activity or the release of urothelial mediators.
环磷酰胺(CPO)和异环磷酰胺(IFO)等细胞毒性药物会产生代谢产物,导致膀胱炎症,从而引起毒理学上的泌尿系统影响。本研究旨在确定这些药物治疗后膀胱传入系统的变化,这些变化可能解释了已报道的泌尿系统不良反应。CPO(100mg/kg)、IFO(200mg/kg)或生理盐水(对照)腹腔给药 24 小时后,在离体膀胱中记录膀胱充盈和药物给药期间的膀胱内压和传入神经活动。在离体膀胱中,最大膀胱充盈时的总传入神经活动从对照动物的 182±13 imp/s 增加到 CPO 处理组的 230±14 imp/s(p<0.05)和 IFO 处理组的 226±17 imp/s(p<0.001)。单纤维分析显示,这种增加是由于低阈值、宽动态范围纤维的活性增强(对照组为 23.3±1.9 imp/s/纤维,CPO 组为 31.5±2.5(p<0.01),IFO 组为 29.9±2.0 imp/s/纤维(p<0.05)。CPO 处理伴随着体内尿频率的增加,但与尿路上皮释放 ATP 或乙酰胆碱、膀胱顺应性或自发性肌肉活动增加无关。此外,CPO 处理也不影响传入神经反应或对嘌呤能、毒蕈碱或烟碱激动剂的压力反应。这是首次报道 CPO 和 IFO 引起的膀胱传入纤维特定群体的变化,即低阈值、宽动态范围纤维的增加。这些作用似乎是直接的,而不是继发于平滑肌活动增加或尿路上皮介质释放。